Related coverage linked through entity extraction aliases.
Aug 20, 2026
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Aug 14, 2026
ASTRO issued updated pancreatic cancer radiation therapy guidelines covering resectable, locally advanced, recurrent, metastatic and palliative disease. The revision replaces 2019 recommendations and supports IMRT, daily image guidance, and respiratory motion assessment.
Aug 05, 2026
The FDA granted Fast Track designation to Oncolytics Biotech's pelareorep combined with a checkpoint inhibitor for advanced squamous cell carcinoma of the anal canal. The designation follows encouraging GOBLET study data and supports development in an estimated $1 billion market with no approved therapies.
Mar 18, 2026
Candel Therapeutics secured $100M royalty funding for CAN-2409 and plans a Q4 2026 BLA submission in prostate cancer. Updated NSCLC phase 2a data showed median overall survival of 25.4 months, with a phase 3 trial planned for Q2 2026.
Jul 08, 2026
Daraxonrasib reduced death risk by 60% versus chemo in Phase 3 pancreatic cancer trial (median OS 13.2 vs 6.7 months). EMA began rolling review; zoldonrasib combo data presented at ESMO GI.
Jun 26, 2026
Recent studies show progress in cancer treatment: HDAC inhibitors enhance pancreatic cancer therapy, AI-guided radiation targets glioblastoma, and reprogrammed tumor cells trigger antitumor immunity. Nanoparticle drug delivery for brain cancer is also being explored.
Aug 09, 2026
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Jul 01, 2026
The FDA approved Novocure's Optune Pax for locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel, based on PANOVA-3 data showing improved overall survival. The device also earned a CE mark in Europe, with a planned launch in Germany.
Jul 08, 2026
Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.
Jun 22, 2026
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
Jun 15, 2026
Studies from ETH Zurich and Cold Spring Harbor Laboratory reveal new vulnerabilities in hard-to-treat lung cancers, including a light-controlled switch that wakes dormant cells and newly identified master regulators.
Jun 17, 2026
PanTher Therapeutics completed dose escalation in its Phase 1b trial of PTM-101 for pancreatic cancer, identifying 400mg as the recommended Phase 2 dose. Other pancreatic cancer updates include ASCO 2026 RASolute 302 data, a Nature study on NDRG1, and a giant acinar cell carcinoma case report.
Jun 28, 2026
FDA granted early access to a pancreatic cancer drug; final ARROW data for pralsetinib in RET+ NSCLC were published. A Sarah Cannon Research Institute official outlined a tissue-agnostic vision and highlighted new oncology research.
Aug 07, 2026
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Jul 31, 2026
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Jun 20, 2026
PancreaSure detected advanced PDAC with 87.9% sensitivity and 97.7% specificity, outperforming CA19-9 alone. PanMETAI, an AI metabolomics model, achieved AUC 0.99 in training and 0.93 in external validation for early PDAC detection.
Aug 08, 2026
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
Mar 21, 2026
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
Jul 05, 2026
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company specializing in True Human monoclonal antibodies. Pipeline candidates include Natrunix and Hutrukin. The company is held by small-cap value ETFs.
Aug 01, 2026
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
